Merck (MRK) Tops Q3 EPS by 4c; Lifts FY15 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
Leerink Partners Reiterates Market Perform on Merck (MRK) Following 3Q EPS Beat
October 28, 2015 9:31 AM EDTLeerink Partners reiterated a Market Perform rating and $67.00 price target on Merck (NYSE: MRK) following the company's 3Q earnings results. MRK reported a $0.04 EPS beat. US sales of Januvia/Janumet increased by 22%, but was benefited by ~$100M due to the timing of consumer buying that is expected to negatively impact future quarters.
Analyst Seamus Fernandez... More
